Recovery and half-life of factor VIII

被引：0
作者：
Koc, Basak [1 ,2 ]
Zulfikar, Bulent [1 ,2 ,3 ]
Ozcan, Hanife
机构：
[1] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey
[2] Inst Oncol, Istanbul, Turkey
[3] Hemophilia Soc Turkey, Istanbul, Turkey
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：52 / 53
页数：2
相关论文
共 50 条
  • [31] CLINICAL APPLICATION OF EXTENDED HALF-LIFE PEGYLATED FACTOR VIII IN CHILDREN WITH SEVERE HAEMOPHILIA A
    Dettoraki, A.
    Michalopoulou, A.
    Mazarakis, M.
    Saslis, S.
    Stamati, I.
    Kapsimali, Z.
    Pergantou, H.
    HAEMOPHILIA, 2022, 28 : 44 - 45
  • [32] In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds
    Josset, Laurie
    Rezigue, Hamdi
    Nougier, Christophe
    Leuci, Alexandre
    Desage, Stephanie
    Lienhart, Anne
    Dargaud, Yesim
    HAEMOPHILIA, 2025, 31 (02) : 224 - 230
  • [33] CLINICAL APPLICATION OF EXTENDED HALF-LIFE FACTOR VIII AND IX IN CHILDREN WITH HAEMOPHILIA A AND B
    Dettoraki, A.
    Michalopoulou, A.
    Saslis, S.
    Kapsimali, Z.
    Mazarakis, M.
    Thymianou, S.
    Stamati, I.
    Pergantou, H.
    HAEMOPHILIA, 2021, 27 : 53 - 54
  • [34] Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
    Mueller, Jens
    Goldmann, Georg
    Marquardt, Natascha
    Poetzsch, Bernd
    Oldenburg, Johannes
    HAMOSTASEOLOGIE, 2020, 40 : S15 - S20
  • [35] COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL
    Peral, C.
    Kim, H. K.
    Rubio-Rodriguez, D.
    Rubio Terres, C.
    VALUE IN HEALTH, 2019, 22 : S421 - S422
  • [36] Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
    Eduardo Megias, Juan
    Bonanad Boix, Santiago
    Martinez Garcia, Maria Fernanda
    Berrueco, Ruben
    Eva Mingot-Castellano, Maria
    Rodriguez Lopez, Manuel
    Canaro, Mariana
    Mateo Arranz, Jose
    Larrode Lecinena, Itziar
    Haya, Saturnino
    Santamaria Ortiz, Amparo
    Albo, Carmen
    Mesegue Medea, Montserrat
    Palomero-Massanet, Antonio
    Vilalta Seto, Noelia
    Calvo Villas, Jose Manuel
    Cid, Ana R.
    Robayo, Gustavo
    Poveda Andres, Jose Luis
    Sanz, Guillermo F.
    Iorio, Alfonso
    BLOOD, 2019, 134
  • [37] Half-life ... What half-life?
    Lewis, BJ
    JOURNAL OF MANAGEMENT IN ENGINEERING, 1998, 14 (01) : 4 - 4
  • [38] HEMOPHILIC PATIENTS WITH AN INHIBITOR TO FACTOR-VIII TREATED WITH HIGH-DOSE FACTOR-VIII CONCENTRATE - RESULTS OF A COLLABORATIVE STUDY FOR THE EVALUATION OF FACTOR-VIII INHIBITOR TITER, RECOVERY AND HALF-LIFE OF INFUSED FACTOR-VIII
    SULTAN, Y
    WHITE, GC
    ARONSTAM, A
    BOSSER, C
    BRACKMANN, HH
    BROCHIER, G
    GORMSEN, J
    MARIANI, G
    ROBERTS, HR
    SCARABIN, Y
    SCHARRER, I
    SCHEIBEL, E
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1986, 28 (02): : 85 - 89
  • [39] Immunogenicity assessment of the first extended half-life factor VIII product, recombinant factor VIII Fc fusion protein (rFVIIIFc), in humans
    Jani, D.
    Pennucci, J.
    Goyal, J.
    Dumont, J. A.
    Allen, G.
    Pierce, G. F.
    Sommer, J. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 583 - 583
  • [40] The half-life of infused factor VIII in patients with hemophilia A is influenced by ABO blood group.
    Vlot, AJ
    MauserBunschoten, EP
    Zarkova, AG
    Haan, E
    Kruitwagen, CLJJ
    Sixma, JJ
    vandenBerg, HM
    BLOOD, 1997, 90 (10) : 690 - 690
12345